Randomized controlled trialHuman
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
The New England journal of medicine, 2023 Dec 14. Lincoff AM, Brown-Frandsen K, Colhoun HM and 14 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2023 Dec 14
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodGlucagon-Like PeptidesHypoglycemic AgentsMyocardial InfarctionObesityOverweightStrokeGlucagon-Like Peptide-1 Receptor AgonistsCardiovascular Agents
Other papers on Semaglutide
Randomized controlled trial · 2025
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Randomized controlled trial · 2021Once-Weekly Semaglutide in Adults with Overweight or Obesity
Randomized controlled trial · 2016Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page